In a 51‑year‑old hypertensive male with serum creatinine 5.4 mg/dL, eGFR 12 mL/min/1.73 m², BUN 31 mg/dL, who is asymptomatic and has no fluid overload, does he require dialysis and should his angiotensin‑II receptor blocker (valsartan) be discontinued?

Does This Patient Need Dialysis?

No, this patient does not require dialysis at this time. With an eGFR of 12 mL/min/1.73 m² (CKD G5), he meets the threshold where dialysis preparation should be discussed, but the absence of uremic symptoms, fluid overload, refractory hyperkalemia, or metabolic acidosis means there is no urgent indication to start dialysis now 1, 2.

Dialysis Initiation Criteria

Dialysis should be initiated based on clinical symptoms and complications, not eGFR alone. The key indications include:

• Uremic symptoms: pericarditis, encephalopathy, bleeding diathesis, intractable nausea/vomiting
• Fluid overload refractory to diuretics
• Hyperkalemia unresponsive to medical management (K+ >6.5 mmol/L or symptomatic)
• Severe metabolic acidosis (pH <7.2 or HCO3 <10 mmol/L)
• Uremic complications: malnutrition, neuropathy

Since this patient is asymptomatic with no fluid retention, watchful waiting with close monitoring is appropriate. However, at eGFR 12, he should be referred to nephrology immediately for dialysis access planning (fistula creation takes 3-6 months to mature) and education about renal replacement options.

---

Should Valsartan Be Stopped?

No, do not routinely discontinue valsartan in this patient. The evidence strongly supports continuing RAS inhibitors even at eGFR <15 mL/min/1.73 m² unless specific complications arise 1, 2.

Guideline-Based Approach to RAS Inhibitors in Advanced CKD

KDIGO 2021 explicitly states (Practice Point 3.2.6): "Consider reducing the dose or discontinuing ACEi or ARB in the setting of either symptomatic hypotension or uncontrolled hyperkalemia despite medical treatment, or to reduce uremic symptoms while treating kidney failure (eGFR <15 ml/min per 1.73 m²)" 1.

The key phrase is "consider"—not "routinely discontinue." The guideline further emphasizes: "Do not routinely discontinue in people with GFR <30 ml/min/1.73 m² as they remain nephroprotective" 2.

When to Continue Valsartan (Current Situation)

Continue the ARB if:

• Blood pressure is controlled without symptomatic hypotension
• Serum potassium remains <5.5-6.0 mmol/L
• No uremic symptoms are present
• Patient is not volume depleted

Monitor within 2-4 weeks: Check BP, serum creatinine, and potassium 1.

When to Reduce Dose or Stop

Discontinue or reduce valsartan only if:

• Symptomatic hypotension develops (dizziness, syncope, falls)
• Uncontrolled hyperkalemia (K+ >6.0 mmol/L) despite potassium-lowering measures (dietary restriction, diuretics, potassium binders)
• Uremic symptoms emerge that might improve with stopping the drug
• Acute creatinine rise >30% within 4 weeks of dose change 1, 2

---

Evidence Supporting Continuation

Multiple studies demonstrate that ARBs remain renoprotective even in advanced CKD:

• Valsartan slows progression in patients with creatinine 1.5-3.0 mg/dL (similar to this patient's 5.4 mg/dL), reducing the rate of GFR decline compared to placebo 3
• Proteinuria reduction persists even at advanced stages (mean creatinine 365 μmol/L ≈ 4.1 mg/dL), with improved glomerular permselectivity 4
• Acute creatinine rises up to 30% that stabilize within 2 months are associated with long-term renal protection, not harm 5, 6

The FDA label for valsartan does not contraindicate use at low eGFR but notes "no data are available in pediatric patients either undergoing dialysis or with a glomerular filtration rate <30 mL/min/1.73 m²" 7—this refers to pediatric patients, not adults.

---

Practical Management Algorithm

Step 1: Assess for Contraindications

• Check serum potassium (if >6.0 mmol/L → implement potassium-lowering measures first)
• Assess for symptomatic hypotension (orthostatic BP drop >20/10 mmHg with symptoms)
• Evaluate for uremic symptoms (nausea, pruritus, altered mental status)

Step 2: If No Contraindications Present

• Continue valsartan at current dose
• Recheck labs in 2-4 weeks: creatinine, potassium, BUN
• Monitor BP at each visit

Step 3: Manage Hyperkalemia Proactively

If potassium rises to 5.5-6.0 mmol/L:

• Dietary potassium restriction (<2 g/day)
• Add or increase loop diuretic (if not volume depleted)
• Consider potassium binders (patiromer, sodium zirconium cyclosilicate)
• Do not stop valsartan unless K+ >6.0 mmol/L and refractory 1

Step 4: Accept Modest Creatinine Increases

• Creatinine rises <30% within 2 months are expected and protective 5, 6
• Only discontinue if creatinine rises >30% within 4 weeks 1

---

Common Pitfalls to Avoid

1. Reflexively stopping ARBs at low eGFR: This removes renoprotection and may accelerate progression to dialysis
2. Stopping for mild hyperkalemia: Implement potassium management strategies first 1
3. Ignoring volume status: Ensure adequate hydration; dehydration exacerbates creatinine rises
4. Not monitoring closely: Labs must be checked 2-4 weeks after any dose change 1
5. Combining multiple RAS inhibitors: Never use ACEi + ARB + direct renin inhibitor together 1

---

Immediate Action Plan

1. Continue valsartan unless contraindications emerge
2. Refer to nephrology urgently for dialysis access planning and CKD G5 management
3. Check labs in 2 weeks: creatinine, BUN, potassium, bicarbonate
4. Educate patient on signs of hyperkalemia (weakness, palpitations) and uremia (nausea, confusion, pruritus)
5. Optimize BP control: Target <130/80 mmHg using standardized measurement 1
6. Avoid nephrotoxins: NSAIDs, contrast agents (if unavoidable, use protocols for eGFR <15) 2

The combination of asymptomatic presentation and guideline-supported continuation of RAS inhibition makes this a straightforward case for conservative management with close monitoring rather than immediate dialysis or drug discontinuation.